Schrodinger Combines Predictable Software Growth with High-Upside Drug Discovery for Asymmetric Returns
Schrodinger, Inc. operates a unique hybrid business model at the intersection of life sciences and technology. The company has developed and commercialized a proprietary, physics-based computational platform that serves as the foundation for two distinct, yet synergistic, business segments. This dual structure is central to the company's strategy and the investment thesis.
The Software segment provides access to its industry-leading molecular modeling and simulation software suite to a global client base. This includes over 1,700 customers across the biopharmaceutical and industrial sectors, as well as academic institutions and government laboratories. This segment functions similarly to a high-growth software-as-a-service (SaaS) business, generating a stable and recurring revenue stream that forms the financial bedrock of the company.
The Drug Discovery segment leverages the same proprietary computational platform to design and advance a portfolio of novel therapeutic candidates. This work is conducted both through wholly-owned proprietary programs and in collaboration with major pharmaceutical partners. This segment represents the high-risk, high-reward component of the business, offering significant, albeit uncertain, long-term value creation potential through the achievement of research, development, and commercial milestones, as well as future royalties.
The central investment question for Schrodinger is whether the predictable, moderate growth of its software business can provide a stable financial foundation to fund the development of a proprietary drug pipeline that could unlock transformative value for shareholders. The analysis must weigh the tangible, growing value of the software platform against the more speculative, binary outcomes inherent in drug development to determine if the current market valuation offers a compelling asymmetric risk/reward profile.
Schrodinger's strategy is built upon the synergistic relationship between its two core segments. The software business provides financial stability and market validation, while the drug discovery business aims to deliver exponential value growth and, in turn, demonstrate the superior capabilities of the underlying platform.
The software business is the company's established and predictable revenue engine, characterized by a clear growth strategy and a strong competitive moat.
Primary Revenue Driver: Land and Expand: Schrodinger's core software growth strategy focuses on deepening its penetration within its existing customer base, particularly among the world's largest biopharmaceutical companies. Rather than relying on a high volume of new customer acquisitions, the company aims to expand the annual contract value (ACV) of its current clients as they integrate the platform more deeply into their research and development workflows. This strategy has proven effective, as evidenced by key performance indicators from 2024. The number of customers with an ACV of at least $5 million doubled from four to eight, and the ACV of its top 10 customers grew by an impressive 43% to $73.1 million. This demonstrates a clear trend of customers scaling up their usage and reliance on Schrodinger's tools over time.
Competitive Moat: High Switching Costs & Customer Stickiness: The platform's scientific rigor and its deep integration into the complex, multi-year R&D processes of its customers create significant switching costs. Once a research team standardizes its workflows, data, and models on the Schrodinger platform, migrating to a competitor becomes a costly and disruptive endeavor. This "stickiness" is reflected in the company's exceptionally high customer retention rates. For 2024, the retention rate for customers with an ACV of at least $500,000 was 100%, and it was 95% for customers with an ACV of at least $100,000.
Growth Initiatives: To sustain growth, Schrodinger is focused on expanding its platform's capabilities and accessibility. A key initiative involves developing streamlined workflows to make the software more accessible to bench scientists who are not computational chemistry specialists. Furthermore, the company is expanding into adjacent high-value areas, such as biologics informatics and a predictive toxicology initiative. This toxicology project, partially funded by the Gates Foundation, aims to reduce the reliance on animal testing and is a significant strategic investment in a new data-as-a-service offering.
The drug discovery segment is the engine for potential transformative growth, designed to capture a greater share of the economic value created by the company's platform.
Strategy: Validation Through Collaboration: The primary strategy for the drug discovery arm is to identify and advance novel drug candidates to a key value inflection point and then partner with large, well-capitalized pharmaceutical companies for later-stage clinical development and commercialization. This approach serves two critical functions: it provides external, expert validation of the platform's drug-hunting capabilities, and it secures significant, non-dilutive funding in the form of upfront payments and potential downstream milestones. The collaboration with Novartis, which included a $150 million upfront payment received in January 2025, is the flagship example of this strategy's successful execution.
Proprietary Pipeline: The Ultimate Value Driver: In parallel with its collaboration strategy, Schrodinger is selectively advancing a pipeline of wholly-owned assets in therapeutic areas with high unmet needs, primarily oncology. The current clinical-stage programs include SGR-1505 (a MALT1 inhibitor) and SGR-3515 (a Wee1/Myt1 co-inhibitor). While these programs carry the full cost and risk of development, their success would allow Schrodinger to capture the entire economic value of a commercialized drug, representing the most significant potential upside for the company's valuation. The company is actively exploring strategic partnership opportunities for SGR-1505 to accelerate its mid-stage development.
Schrodinger's market position is underpinned by several key differentiators that create a durable competitive advantage.
Physics-Based Platform: The company's core technological moat is its platform's foundation in first-principles physics-based modeling, exemplified by its Free Energy Perturbation (FEP+) technology. Management asserts that this approach provides a higher degree of accuracy in predicting molecular binding affinity compared to methods that rely solely on artificial intelligence and machine learning (AI/ML). Schrodinger employs a hybrid approach, using its physics-based simulations to generate vast quantities of high-quality, proprietary data, which then serves as a superior training set for its own AI/ML models. This creates a virtuous cycle where physics improves the AI, and the AI accelerates the physics-based discovery process.
Integrated Business Model: The symbiotic relationship between the software and drug discovery segments is a unique structural advantage. The drug discovery programs serve as the ultimate real-world test case and validation for the software platform. Successes in the pipeline are a powerful marketing tool that can drive software sales and demonstrate a clear return on investment for customers. This feedback loop, where internal application drives external adoption, is a dynamic that pure-play software vendors or standalone biotech companies cannot replicate.
Competitive Landscape: While the company's platform is widely considered the "gold standard" in its niche , the computational chemistry and drug discovery market is competitive. Key commercial competitors include Dassault Systèmes (BIOVIA), Chemical Computing Group (MOE), and Certara. The space also includes numerous smaller private companies and widely used open-source tools like AutoDock. Schrodinger's primary defense against these competitors is its scientific reputation, the validated accuracy of its physics-based methods, and the breadth of its integrated platform.
The recent decline in software gross margin is an important indicator of the company's strategic evolution. In the second quarter of 2025, software gross margin fell to 68%, a notable decrease from 80% in the same period of the prior year. The company explicitly attributed this compression to the costs associated with its new predictive toxicology initiative. This should not be viewed as a simple erosion of profitability but rather as a deliberate investment to shift the business model. This initiative moves Schrodinger beyond being a pure software tools provider towards a more integrated Platform-as-a-Service (PaaS) model that delivers predictive data. While this model inherently carries higher hosting and computational costs, leading to a structurally lower gross margin profile, it also has the potential to significantly expand the company's total addressable market and create an even stickier customer relationship, justifying the margin trade-off in the long term.
An analysis of Schrodinger's recent financial performance reveals a company in a state of transition, characterized by steady growth in its core software business, lumpy but potentially significant contributions from its drug discovery arm, and a strategic focus on managing its operating expenses and cash burn as it invests for future growth.
For the full fiscal year 2024, Schrodinger reported total revenue of $207.5 million. The software segment was the primary contributor, with revenue growing a solid 13.3% year-over-year to $180.4 million. The drug discovery segment contributed a more variable $27.2 million. Reflecting its heavy investment in research and development, the company posted a net loss of $187.1 million for the year.
The first half of 2025 showed continued top-line momentum. Q1 2025 was an exceptionally strong quarter, with total revenue reaching $59.6 million, a 63% increase year-over-year, largely driven by the timing of several large, early software contract renewals.
Q2 2025 demonstrated more normalized but still solid growth, with total revenue of $54.8 million, up 16% from the prior-year period. This was composed of $40.5 million in software revenue (up 15%) and $14.2 million in drug discovery revenue (up 19%). Encouragingly, the company showed progress in managing its costs, with the net loss for the quarter narrowing to $43.2 million from $54.0 million in Q2 2024.
From a financial health perspective, Schrodinger remains well-capitalized, ending the second quarter of 2025 with $462 million in cash, cash equivalents, and marketable securities. Despite this strong cash position, the company is consistently burning cash to fund its operations and pipeline. A key positive development is management's focus on efficiency, highlighted by a $30 million expense reduction initiative announced in May 2025. As a result, the company expects cash used in operating activities to be significantly lower in 2025 compared to 2024.
As of its Q2 2025 earnings report, Schrodinger reaffirmed its full-year financial guidance. The company continues to expect:
Software revenue growth in the range of 10% to 15%.
Drug discovery revenue between $45 million and $50 million.
Software gross margin between 74% and 75%.
Notably, the company updated its outlook for operating expenses, now expecting them to be lower in 2025 than they were in 2024. This is an improvement from previous guidance and reflects the impact of its cost control measures.
As of late September 2025, Schrodinger's stock price was approximately $19.06 per share, corresponding to a market capitalization of approximately $1.40 billion. With 73.61 million shares outstanding, the company is not profitable on a trailing twelve-month (TTM) basis, rendering price-to-earnings (P/E) ratios not meaningful.
The most relevant valuation metrics for Schrodinger are based on revenue:
Price-to-Sales (P/S) Ratio: Approximately 5.85x on a TTM basis.
Enterprise Value-to-Sales (EV/Sales) Ratio: Approximately 6.6x on a TTM basis.
Price-to-Book (P/B) Ratio: Approximately 4.09x.
These multiples reflect a company valued on the growth prospects of its software platform and the embedded optionality of its drug discovery pipeline, rather than on current earnings.
Note: FY 2025 Guidance figures are calculated based on the company's stated growth rates and revenue ranges. H1 2025 actuals are derived from Q1 and Q2 results. FY 2023 data from.
An investment in Schrodinger carries a unique risk profile stemming from its hybrid business model. It is exposed to both the cyclical challenges of the biotechnology industry and the inherent binary risks of clinical drug development.
Clinical Trial and Pipeline Risk: This is the most significant and acute risk facing the company. The value of the drug discovery segment is entirely dependent on the successful advancement of its pipeline candidates. The abrupt discontinuation of the SGR-2921 program for acute myeloid leukemia in August 2025, following trial-related deaths, serves as a stark reminder of this reality. This event led to a sharp decline in the stock price and highlighted the binary nature of drug development. A similar failure or disappointing data from the remaining key assets, SGR-1505 or S_S3515, would severely impair the company's valuation and investment thesis.
Collaboration Dependency: A substantial portion of the drug discovery segment's recognized and future revenue is dependent on achieving milestones from a small number of key collaboration partners, most notably Novartis. The termination of a major collaboration, or a partner's decision to deprioritize a partnered program, would have a material negative impact on revenue forecasts and could be perceived as a negative signal about the platform's capabilities.
Intensifying Competition: The field of computational drug discovery is dynamic and increasingly crowded. While Schrodinger currently holds a leadership position, it faces competition from large, well-resourced companies like Dassault Systèmes, specialized software providers, and a growing number of AI-native startups. Continued innovation from these competitors could, over time, erode Schrodinger's technological lead, market share, or pricing power.
History of Losses and Cash Burn: Schrodinger has a history of significant operating losses and is not forecast to become profitable for at least the next three years. The company's strategy requires substantial ongoing investment in R&D for both platform improvement and pipeline advancement. While its current cash position is strong, the company must continue to manage its cash burn prudently to avoid the need for a potentially dilutive capital raise in a challenging market environment.
Biotechnology Funding Environment: The health of the broader biotechnology capital markets is a direct driver for Schrodinger's software business. In the Q2 2025 earnings call, management noted "persistent biotech environment challenges" as a headwind, as smaller, cash-constrained biotech companies are key customers. A prolonged downturn in biotech funding would likely slow new customer acquisition and could lead existing customers to curtail spending, acting as a direct brake on software revenue growth.
Drug Pricing and Regulatory Pressures: The entire pharmaceutical industry faces ongoing pressure from governments and payors to control drug prices. This could impact the long-term economic models for drug development, potentially reducing the value of future collaboration deals or the commercial potential of Schrodinger's proprietary assets.
Evolving Regulatory Landscape: The regulatory pathway for drug approval is subject to change. While shifts such as the FDA's stated plan to phase out certain animal testing requirements could be a significant long-term tailwind for Schrodinger's predictive toxicology platform, other unforeseen regulatory hurdles could increase development timelines and costs.
While the discontinuation of the SGR-2921 program was a clear clinical and stock price negative, it also provides a window into the company's strategic discipline. The decision, though painful, prevented the allocation of further capital to a program with an unfavorable risk-benefit profile. This action allows for the reallocation of financial and human resources to the remaining, more promising clinical assets, SGR-1505 and SGR-3515. This pivot aligns with the company's broader $30 million expense reduction initiative and demonstrates a rational approach to R&D portfolio management. For investors, this disciplined, if difficult, decision can be seen as a positive indicator of management's commitment to efficient capital allocation, clarifying the focus on the assets that hold the most potential to drive future value.
This section presents a five-year forecast for Schrodinger's financial performance and share price under three distinct scenarios: Base, High, and Low. The analysis is grounded in the company's reported financials and guidance, with transparent assumptions driving the projections through fiscal year 2029.
Core Modeling Inputs (Provenance):
Current Share Price (Sep 24, 2025): $19.06
Shares Outstanding (Diluted): 73.61 million
Base Year (FY 2024) Revenue: Software: $180.4M; Drug Discovery: $27.2M
Current Year (FY 2025) Guidance: Software Growth: 10-15%; Drug Discovery Revenue: $45-50M
Base Year (FY 2024) Operating Expenses: $341.4M
Current Year (FY 2025) Operating Expense Guidance: Lower than FY 2024
Cash & Equivalents (Q2 2025): $462.3M
This scenario assumes the company continues to execute on its current strategy without any major unexpected breakthroughs or setbacks. The software business remains the stable growth engine, and the drug discovery pipeline progresses, leading to a gradual de-risking and value appreciation.
Software Revenue Growth: Begins at 12.5% in 2025 (midpoint of guidance) and decelerates by 50 basis points per year to 10.5% in 2029, reflecting market maturation.
Drug Discovery Revenue: Averages $65 million annually from 2026-2029, reflecting the amortization of the existing Novartis collaboration plus one new mid-sized partnership deal.
Software Gross Margin: Stabilizes at 75%, consistent with 2025 guidance.
Operating Expenses: Decrease by 2% in 2025 as guided, then grow at a disciplined 5% annually, balancing investment with cost control.
Terminal EV/Sales Multiple: 6.0x. This multiple is applied to projected 2029 total revenue, reflecting a valuation consistent with the current multiple for a business with maturing software growth and a de-risked but not yet proven pipeline.
This scenario envisions significant positive catalysts. The software platform's competitive advantage widens, and a key proprietary drug program is successfully de-risked, leading to a substantial value inflection.
Software Revenue Growth: Begins at 15% in 2025 (high end of guidance) and remains robust, decelerating to only 12% by 2029 due to increased adoption and pricing power.
Drug Discovery Revenue: Averages $125 million annually from 2026-2029. This is driven by a major new partnership for SGR-1505 following positive Phase 2 data, including a large upfront payment amortized over the period.
Software Gross Margin: Expands to 77% due to operating leverage and higher pricing on software sales.
Operating Expenses: Grow at a faster rate of 8% annually after 2025 to support accelerated pipeline development and commercial readiness.
Terminal EV/Sales Multiple: Expands to 9.0x. The market assigns a premium valuation to reflect a significantly de-risked, high-value drug pipeline and accelerating software growth.
This conservative scenario models the impact of persistent industry headwinds and a significant clinical trial disappointment. The company is forced to retrench and focus on cash preservation.
Software Revenue Growth: Begins at 10% in 2025 (low end of guidance) and decelerates more sharply to 6% by 2029 as the challenging biotech funding environment persists.
Drug Discovery Revenue: Declines to an average of $35 million annually from 2026-2029, reflecting the roll-off of existing collaborations with no major new deals signed.
Software Gross Margin: Compresses to 72% due to increased pricing pressure from competitors and budget-constrained customers.
Operating Expenses: Remain flat after the 2025 reduction as the company implements strict cost controls and curtails R&D investment.
Terminal EV/Sales Multiple: Compresses to 4.0x. The market assigns a lower multiple reflecting slower growth prospects and a pipeline that has failed to deliver on its promise.
The projected share price is calculated by applying the terminal EV/Sales multiple to 2029 revenue, adjusting for the projected net cash/debt position at the end of the period, and dividing by the projected number of fully diluted shares outstanding (assuming modest 1% annual dilution).
To derive a single price target that reflects the asymmetric nature of the investment, subjective probabilities are assigned to each scenario. Given the steady nature of the software business and the binary risks in the pipeline, a higher weight is assigned to the Base Case.
High Case Probability: 20%
Base Case Probability: 55%
Low Case Probability: 25%
The probability-weighted 5-year price target is calculated as follows:
This analysis suggests a probability-weighted price target of approximately $34.00, representing a potential 5-year CAGR of approximately 12.3%.
Asymmetric Upside Potential.
This scorecard provides a qualitative assessment of Schrodinger across ten key operational and strategic dimensions, with each scored on a scale of 1 to 10.
Management Alignment: 6/10 Management compensation is a standard mix of base salary, performance-based cash incentives, and long-term equity awards, which provides a reasonable alignment with shareholder interests. The inclusion of performance-based restricted stock units (PRSUs) is a positive feature. However, the company's insider trading policy allows for exceptions to its prohibition on pledging shares, as demonstrated by a pledge from a co-founder, which introduces a minor governance concern. On the positive side, the recently implemented $30 million cost reduction program suggests a management team that is responsive to market conditions and focused on efficient capital deployment.
Revenue Quality: 8/10 The quality of revenue from the software segment is excellent. It is characterized by high-value, multi-year contracts and is supported by exceptionally strong customer retention rates, which were 100% for customers with over $500k in ACV and 95% for those over $100k in ACV in 2024. This creates a highly predictable, recurring revenue stream. The overall score is tempered by the drug discovery segment, where revenue is inherently low-quality, lumpy, and dependent on binary clinical and regulatory events.
Market Position: 9/10 Schrodinger is widely regarded as the scientific and commercial leader in the physics-based computational drug discovery market, often referred to as the "gold standard". The company is actively gaining wallet share within its most important customer accounts, evidenced by the 43% growth in ACV from its top 10 customers in 2024. While formidable competitors exist, Schrodinger's scientific pedigree, integrated platform, and decades of focused R&D have established a powerful market position.
Growth Outlook: 7/10 The outlook is favorable but bifurcated. The software business has a clear pathway to durable mid-teens percentage growth, driven by deeper customer penetration and platform expansion. The drug discovery segment offers immense, albeit highly uncertain, long-term growth potential. The recent clinical failure of SGR-2921 has tempered the near-term outlook for the pipeline , but the underlying trend of platform adoption remains strong, and analyst consensus points to significant long-term upside.
Financial Health: 7/10 The company's balance sheet is strong, with a robust cash position of $462 million as of mid-2025 and no significant debt. Liquidity ratios are healthy, with a Quick Ratio of 3.13 and a Current Ratio of 3.30. This strength is offset by the company's lack of profitability and negative free cash flow, which makes it reliant on its existing cash reserves to fund operations. The stated goal of significantly reducing cash burn in 2025 is a crucial and positive step.
Business Viability: 8/10 The long-term viability of the business is high. The established, market-leading software business provides a stable foundation that ensures the company's survival and continued operation, distinguishing it from typical pre-revenue biotechnology firms that are wholly dependent on clinical outcomes. Furthermore, the platform has applications beyond pharmaceuticals in areas like materials science, offering long-term diversification potential.
Capital Allocation: 7/10 Schrodinger has a clear and logical capital allocation strategy: reinvest cash flow from the software business and collaboration payments to fund the high-upside proprietary drug pipeline. The decision to terminate the SGR-2921 program, while difficult, demonstrated capital discipline. The company appropriately does not pay a dividend, instead prioritizing reinvestment for growth. The recent cost-cutting program further reinforces a focus on efficiency.
Analyst Sentiment: 8/10 Sentiment from the analyst community is overwhelmingly positive. The consensus rating is a 'Buy' or 'Strong Buy', with approximately 69% of covering analysts recommending the stock. The average 12-month price target of approximately $28 per share suggests analysts see significant upside from the current price levels.
Profitability: 2/10 The company is significantly unprofitable on a GAAP basis, reporting a net loss of $187.1 million in 2024 and consistently negative returns on equity, assets, and invested capital. Profitability is not a near- or medium-term objective, as the company continues to make substantial investments in R&D to build out its drug discovery pipeline and enhance its platform.
Track Record: 5/10 Since its IPO in February 2020, Schrodinger's track record of creating shareholder value is mixed. The stock is trading substantially below its all-time highs reached in 2021. While management has successfully grown the software business and executed major collaboration agreements, the company has yet to deliver a pivotal, value-creating clinical success or generate sustained positive returns for shareholders.
Overall Blended Score: 6.7 / 10
Platform Powerhouse.
Schrodinger presents a complex and compelling investment case, characterized by a unique business structure that offers both a degree of stability and significant long-term upside potential. The overall outlook hinges on the successful execution of its dual-pronged strategy.
The investment thesis can be framed by the concepts of a "floor" and a "ceiling." The valuation floor is provided by the high-quality software business. Its market leadership, sticky customer base, and clear path to durable double-digit growth provide a tangible and growing stream of cash flows that offers a fundamental backstop to the company's valuation. The ceiling, or the source of potential transformative returns, is the drug discovery pipeline. This segment provides multiple "shots on goal" in high-value therapeutic areas. The successful development and commercialization of even a single proprietary or partnered drug could result in a valuation that is a multiple of the company's current market capitalization.
Key near-term catalysts that could unlock value include:
The presentation of initial Phase 1 clinical data for the Wee1/Myt1 inhibitor, SGR-3515, which is expected in the fourth quarter of 2025.
The signing of a major strategic partnership for the mid-stage development of the MALT1 inhibitor, SGR-1505, which would provide external validation and non-dilutive funding.
Continued evidence of accelerating adoption within high-ACV software customers in quarterly financial reports.
The primary risks remain heavily concentrated in the drug discovery segment. The foremost risk is clinical trial failure for one of its key remaining assets, SGR-1505 or SGR-3515. Other significant risks include a prolonged downturn in the biotech sector further pressuring software sales, and a failure to continue managing cash burn effectively, which could necessitate a dilutive capital raise from a position of weakness.
In conclusion, an investment in Schrodinger is a venture-capital-style investment in a scientifically validated, best-in-class platform with multiple opportunities to generate significant value, backstopped by a high-quality, growing software business. The current valuation, particularly following the setback with SGR-2921, appears to ascribe limited value to the drug discovery pipeline. For investors with a long-term time horizon and a high tolerance for the inherent risks of biotechnology, the asymmetric profile between the potential upside from a clinical success and the downside cushioned by the software segment may present a compelling opportunity.
Science-Backed Asymmetry.
As of late September 2025, Schrodinger's stock is trading around $19.06. The price is situated well below its 200-day simple moving average of approximately $21.78 and its 50-day moving average of approximately $20.12, indicating a bearish to neutral long-term trend. The stock has been consolidating near the lower end of its 52-week range of $16.60 to $28.47 following the sharp price decline in mid-August caused by the discontinuation of the SGR-2921 program. The short-term outlook is likely to remain news-driven, with the stock potentially trading in a range until the next major clinical data catalyst, expected in the fourth quarter of 2025.
Awaiting Catalyst.
View Schrodinger Inc (SDGR) stock page
Loading the interactive version of this report…